Sign inCreate account

Report workspace

Add to folder
NCT00746473COMPLETEDanonymous

Assessment of Cytokine Values in Serum and by Specific cDNA Amplification and Detection Using RT-PCR in HIV-1 Infected Individuals With and Without Highly Active Anti-Retroviral Therapy (HAART)

Sponsor

Source record

UPECLIN HC FM Botucatu Unesp

Phase

Source record

Completed (Observational Study)

Modality

AI-normalized

RNA therapy

Target

AI-normalized

Cytokine signaling pathways, specifically focusing on TNF-a, IL-2, INF-g, IL-4, and IL-10 in the context of HIV-1 infection and HAART treatment.

Indication / condition

AI-normalized

HIV Infections

Intervention

Source record

Detailed source ingestion pending.

Source & freshness

Source record

NCT ID

NCT00746473

Original source

ClinicalTrials.gov

Source last updated

Sep 04, 2008

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00746473

Title

Assessment of Cytokine Values in Serum and by Specific cDNA Amplification and Detection Using RT-PCR in HIV-1 Infected Individuals With and Without Highly Active Anti-Retroviral Therapy (HAART)

Sponsor

UPECLIN HC FM Botucatu Unesp

Status

COMPLETED

Phase

Completed (Observational Study)

Condition raw

HIV Infections

Condition normalized

HIV Infections

Modality raw

RNA therapy

Modality normalized

RNA therapy

Target raw

Cytokine signaling pathways, specifically focusing on TNF-a, IL-2, INF-g, IL-4, and IL-10 in the context of HIV-1 infection and HAART treatment.

Target normalized

Cytokine signaling pathways, specifically focusing on TNF-a, IL-2, INF-g, IL-4, and IL-10 in the context of HIV-1 infection and HAART treatment.

Interventions

Detailed source ingestion pending

Public preview

Source record

This study provides valuable insights into the immunological profiles of HIV-1 infected individuals under different treatment regimens, particularly the effects of HAART on cytokine levels. The findings could inform the development of novel therapeutic strategies aimed at modulating immune responses in HIV patients. Given the ongoing global demand for effective HIV treatments, this research may enhance competitive positioning for companies developing immunomodulatory therapies. Additionally, the study's completion suggests that the data could be leveraged for further research or partnerships, particularly in the context of combination therapies targeting immune modulation.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Assessment of Cytokine Values in Serum and by Specific cDNA Amplification and Detection Using RT-PCR in HIV-1 Infected Individuals With and Without Highly Active Anti-Retroviral Therapy (HAART)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 17, 2026

NCT ID

NCT00746473

Status

COMPLETED

Phase

Completed (Observational Study)

Sponsor

UPECLIN HC FM Botucatu Unesp

Executive brief

Investment-Ready Snapshot

This study provides valuable insights into the immunological profiles of HIV-1 infected individuals under different treatment regimens, particularly the effects of HAART on cytokine levels. The findings could inform the development of novel therapeutic strategies aimed at modulating immune responses in HIV patients. Given the ongoing global demand for effective HIV treatments, this research may enhance competitive positioning for companies developing immunomodulatory therapies. Additionally, the study's completion suggests that the data could be leveraged for further research or partnerships, particularly in the context of combination therapies targeting immune modulation.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 04, 2008
Internal syncJun 17, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00746473

Indication

HIV Infections

Modality

RNA therapy

Target

Cytokine signaling pathways, specifically focusing on TNF-a, IL-2, INF-g, IL-4, and IL-10 in the context of HIV-1 infection and HAART treatment.

Intervention

Not reported

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.